Objectives/Hypothesis: To evaluate the indications, complications, and device life of the Provox NiD in a large cohort at a tertiary US cancer center.
INTRODUCTION
Tracheoesophageal puncture (TEP) remains the gold standard for alaryngeal voice restoration after total laryngectomy. 1 The appropriate selection and placement of a tracheoesophageal (TE) voice prosthesis that is well matched and acceptable to patients is key to successful voice restoration. The TE voice prosthesis is a one-way silicone valve that is placed into the TEP to allow phonatory air through the puncture and prevent aspiration. Despite the multitude of available prostheses, all depend on occlusion of the tracheostoma to direct pulmonary air through the prosthesis to vibrate the pharyngoesophagus for speech production.
TE prostheses vary according to a variety of parameters, including length, diameter, and method of insertion, and are mainly divided into two types: nonindwelling and indwelling prostheses. Nonindwelling prostheses can be placed by trained medical professionals or by nonclinicians including the TE speaker him-or herself. Alternatively, placement of indwelling prostheses has been approved only by medical professionals. The choice of a nonindwelling or indwelling prosthesis is based on general indicators that include patient characteristics and TE speech quality, the ability of the prosthesis to alleviate complications associated with leakage and aspiration, and device life. Patient preference often revolves around the ease of TE speech production and the cost of the prosthesis, both of which are influenced by the above categories. To date, experience and data support the popularity of the indwelling device over the nonindwelling device because of patient-perceived improvement in TE speech, reduced leakage, and increased device life. 1 The Provox NiD voice prosthesis (Atos Medical, H€ orby, Sweden) has gained popularity in the United States since it was cleared for marketing by the US Food and Drug Administration (FDA) in 2005. 2 Although marketed as a nonindwelling prosthesis, the NiD offers advantages that may make it an attractive often lowercost alternative to the indwelling prostheses. Our experience in the past 8 years suggests that this device offers high patient satisfaction, better than expected durability in patients with early leakage, and favorable voice quality. Others have also reported encouraging results, including lower airflow resistance during speech production, less prosthetic dislodgment, and better voice satisfaction over other nonindwelling prostheses. 3 We, therefore, sought to describe our practice patterns and outcomes using the Provox NiD in a large cohort of patients in a tertiary US cancer center. The primary purpose of this study was to describe the general indicators, device life, and complications associated with use of the NiD. We also discuss the NiD as a low-cost alternative to indwelling prostheses.
MATERIALS AND METHODS

Study Design
A longitudinal retrospective cohort was examined. All laryngectomized patients with a TEP who used a Provox NiD at the University of Texas MD Anderson Cancer Center (MDACC) between March 1, 2005 and September 30, 2011 were eligible for inclusion. All consecutive laryngectomy patients seen in the study period (N 5 522) were examined, and 186 who had an NiD placed were included. Customized NiD prostheses 4 were excluded from analysis. Institutional review board approval and a waiver of informed consent were obtained.
TEP Management at MDACC
Both primary and secondary TEP are performed at MDACC. A red rubber catheter (12-14 Fr) is used to stent the TEP in the immediate postoperative setting. A voice prosthesis is placed 7 to 10 days postoperatively after primary TEP and 3 to 5 days after secondary TEP. Standard practice is to dilate the TE tract to 18 Fr and insert a 16-or 17-Fr prosthesis on the date of initial prosthetic fitting. A variety of indwelling and nonindwelling voice prostheses are used (InHealth Technologies, Carpinteria, CA; Atos Medical). Prostheses are selected at the discretion of the treating clinician based on product specifications and patient feedback regarding voice satisfaction and comfort. The NiD is frequently chosen as the initial product over other types of nonindwelling devices because our early experience suggested that many patients perceived easy voicing abilities using the NiD.
Although the FDA cleared the NiD for use as a nonindwelling device, and the intended use of the device per the Instructions for Use reads, "The Provox NiD voice rehabilitation system is intended for use in prosthetic voice rehabilitation after total laryngectomy only by patients who have been trained in the use of the device and, as assessed by the clinician who prescribes the device, have demonstrated the ability to understand and consistently follow the Instructions for Use without clinician supervision" (Atos Medical), in our practice some patients elect to use the NiD similarly to an indwelling device based on: 1) cleaning of the NiD in situ by the patient, and 2) replacement of the device exclusively by a trained clinician. That is, patients using the NiD similarly to an indwelling device at our institution do not change their own prosthesis. However, all patients who use the NiD prosthesis are trained in the care and management of the device per the manufacturer's Instructions for Use.
Variables
Data sources included the MDACC TEP Tracking Database and retrospective review of the electronic medical records.
Three domains were reviewed, including: general indicators, device life, and complications associated with use of the NiD. Tumor staging, treatment, anatomy, and independence for TEP management were classified as general indicators. Device life was calculated in days from the insertion date to the removal date. Prostheses that dislodged or were removed outside of MDACC with no documented date of removal in the medical record were excluded from analysis of device life. For device life calculations, "standard indwelling" prostheses included the Provox2, Blom-Singer CLASSIC Indwelling, and Provox Vega. "Other nonindwelling" prostheses combined all nonindwelling devices except the NiD and included the Blom-Singer Low Pressure, Blom-Singer Duckbill, Bivona Ultra Low, and Bivona Duckbill. Aspiration of the NiD was confirmed radiographically or per endoscopy. Retail costs of indwelling prostheses generally range from $189 to $1,883 compared with nonindwelling costs that range from $45 to $98. Exact product costs vary according to manufacturer and institutional pricing, but in general indwelling devices remain more costly.
The first use of the NiD was classified as "initial fit" among patients whose first prosthesis placed into a new TEP was an NiD, or "switch" among patients fit with an NiD after trying other voice prostheses. Indications for switch included difficulty voicing, gastric filling, and/or early prosthetic leakage through the valve (<8 weeks); the indication was considered unspecified when no indication for placement was specified in the medical record. Pre-existing early leakage was further stratified as occurring <2 weeks, 2 to 4 weeks, or 5 to 8 weeks after placement. Leakage around the prosthesis was not queried as an indicator for switching to the NiD. In our practice, the standard NiD is not used to manage leakage around a prosthesis because of the small diameter of the esophageal flange.
Statistical Methods
Descriptive statistics were calculated to summarize general indicators, device life, and complications. Kaplan-Meier survival analysis was used to examine prosthetic life. The logrank test was performed to assess the differences between NiD subgroups, stratified by indications for removal, follow-up period, radiotherapy history, extent of surgery, and pre-existing early leakage. Device life of the NiD versus other prostheses was compared within subjects of NiD users. Statistical significance was considered at a 5 .05. Statistical analyses were performed using the STATA data analysis software, version 10.0 (StataCorp LP, College Station, TX).
RESULTS
Patient Cohort
The study population included 186 patients who had an NiD placed at MDACC between 2005 and 2011, with median follow-up of 21.4 months (range, 0-73.4 months). Table I summarizes demographic, disease, and treatment characteristics. The median age of patients was 59 years (range, 33-86 years); 82% (152 of 186) were male. Most (111 of 186, 60%) had a history of glottic or subglottic cancer. Seventy-three percent (135 of 186) underwent total laryngectomy, and the remainder required extended surgery including a partial (33 of 186, 18%) or total pharyngectomy (18 of 186, 10%). The pharynx was closed primarily in most patients (128 of 186, 69%). Eighty-seven percent (162 of 186) had a history of radiation therapy, 54% (100 of 186) prior to laryngectomy and 33% (62 of 186) postoperatively. More than half of patients had primary TEP (102 of 186); 13 (7%) patients who underwent primary TEP required repeat puncture during the study period. Fifty-seven percent (106 of 186) of patients had NiD prostheses replaced by speech pathologists exclusively, 16% (30 of 186) selfreplaced exclusively, and 27% (50 of 186) alternated between replacement by a speech pathologist and selfreplacement.
Device Characteristics
A total of 2,614 voice prostheses were placed in the 186 patients during the study period. Of the prostheses placed, 28% (n 5 727) were NiD prostheses, among which 675 noncustomized NiDs were examined in this analysis. The most common sizes were 20 Fr in diameter, and 10 mm (115 of 675, 17%) and 8 mm (114 of 675, 17%) in length. Table II presents device specifications for the 675 NiDs. Figure 1 shows the indications for first use of an NiD among the 186 subjects. The NiD was selected at initial fit because of the indication for a nonindwelling device in 41 (22%) patients, whereas 145 (78%) switched to an NiD after wearing another type of prosthesis. Prosthetic problems cited at the time of switching to an NiD in 116 (62%) patients included early leakage (71 of 186, 38%), difficulty voicing (50 of 186, 27%), and gastric filling (37 of 186, 20%). Thirty-six (19%) patients cited more than one problem when switching to an NiD. Most patients with a history of early leakage when switching to the NiD experienced leakage within 2 weeks of using other devices, and most (44 of 71, 62%) were using an indwelling prosthesis immediately preceding use of the NiD.
Indications for First Use of the NiD
Device Life of NiD
Among the 675 NiD prostheses, 465 had a known device life that contributed to a total follow-up time of 22,204 days (Fig. 2) . The median device life of all NiD prostheses was 30 days (interquartile range [IQR], 11-63 days). Device life of the NiD was further analyzed per stratifications illustrated in Figure 3 . Stratified by indication for removal, median device life of NiD prostheses removed for prosthetic leak was 45 days compared with 15 days when removed for other indications (Fig. 4A, P <.0001) . Median device life in postacute follow-up (>6 weeks after the TEP) was 41 days (Fig.  4B , P <.0001). Seventy-one patients with history of early leak prior to switching to the NiD had a median device life of 53 days. Almost 90% of NiD prostheses (110 of 123, 89.4%) used in patients with a pre-existing leak outlasted the upper limits of previous prosthesis durational thresholds (<2 weeks, 2-4 weeks, or 5-8 weeks). Extent of surgery (P 5.386) did not significantly affect device life of the NiD. Device life was also not significantly affected by radiation history; however, the 12 NiD prostheses placed in patients without a history of radiotherapy (RT) did last longer (median 78 days) than the 216 placed in patients with a history of RT (median 45 days, P 5.190).
NiD device life was then compared to other prostheses used in our cohort of NiD users. Median NiD device life was significantly longer than that of other nonindwelling prostheses (45 days vs. 29 days, P 5.0061) and did not significantly differ from that of standard indwelling devices (45 days vs. 50 days, P 5.4263). Specifically, when stratified by prosthesis type, the median device life to prosthetic leak was 45 days for NiD prostheses (n 5 228 prostheses), 50 days for standard indwelling devices (n 5 414), and 29 days for other nonindwelling devices (n 5 69; Fig. 5 ).
NiD Outcomes
Eighty (12%) of 675 NiD prostheses dislodged. One patient aspirated the NiD into the respiratory tract while attempting to change the device, but the prosthesis was retrieved endoscopically in the clinic. A safety feature of the NiD to prevent aspiration per the manufacturer's Instructions for Use is the attached medallion. In the patient who aspirated the NiD, the medallion had been detached. Overall, 31% of patients continued to use the NiD prosthesis at last follow-up.
DISCUSSION
This study sought to describe our experience using the NiD prosthesis over the course of 6 years. In our clinical practice, we found that the NiD offers a reliable option for patients with diverse indications. Relative to other prostheses, the NiD offers comparable or extended durability, affordability, independent management, and favorable voicing. Outside of the patient population who demonstrate TEP enlargement or leakage around the prosthesis, we have found no particular subgroup of patients for whom use of the standard NiD cannot be attempted. Our sample included patients requiring flap reconstruction (28%), radiation (87%), and TEP formation as primary or secondary procedures (Table I) . Hence, we present our clinical experience in a sample of diverse and complex TE speakers representative of those who are managed in a large tertiary cancer institution.
In this study, patient satisfaction and quantitative voice outcomes were not collected. One of the motivating reasons for examining our outcomes using the NiD was the subjective enthusiasm reported by our patients for this device because of their sense of easy or effortless voice production. We suspect that the larger inner lumen diameter compared with other nonindwelling devices (17 Fr outer diameter [OD], 2.6 mm inner diameter [ID]; and 20 Fr OD, 4 mm ID) provides less resistance to airflow, resulting in less effortful voicing (Fig. 6 illustrates the dimensions of the NiD prostheses.). Our clinical observations are further supported by published data demonstrating better voice satisfaction and lower in vitro airflow resistance of the NiD compared with other popular nonindwelling prostheses. 3 An important result of our analysis was that the device life of the NiD was better than that of other nonindwelling devices and comparable to that of standard indwelling devices worn in our sample of NiD users. The median device life of the NiD was 45 days (IQR, 27-81 days) to failure by prosthetic leakage. This was comparable to the device life of indwelling prostheses in our sample of NiD users and longer than the median device life of 29 days in other nonindwelling prostheses. NiD device life in our sample was also higher than the reported mean of 26 days for low-pressure and duckbill nonindwelling devices published in other series. 5 We surmise that the design of the NiD that combines a larger inner lumen diameter with a dome-shaped valve offers the advantage of comparable and, in some cases, extended durability without compromising vocal effort. Although the life of the NiD was not as long as published median device life for indwelling prostheses (ranging from 89 to 111 days), evidence that the NiD lasts longer than other nonindwelling devices used by TE speakers in our NiD sample suggests that it offers an excellent alternative to the indwelling device for some patients. We acknowledge that other prostheses offer acceptable and sometimes better longevity among patients who were not included in this study. Bias is inherent in comparisons of devices in observational, retrospective studies such as this, and 62% of patients had experienced problems with other prostheses before trying the NiD. Therefore, the results of this study should be interpreted in the context of a within-subject comparison comprised largely of patients who experienced suboptimal longevity or performance with other styles. Our observations regarding device life require confirmation in randomized comparisons.
Our early experience using the NiD suggested that the NiD might be a "problem-solver" for early leakage. Thus, we further examined device life in the subgroup of patients with history of early leakage before switching to the NiD. In our cohort, 38% of patients presented with a history of early leakage prior to switching to the NiD, and 89% in this subgroup experienced improved device life with the NiD. Although not an intended indication for use by the manufacturer, our analysis suggests that the NiD may offer an affordable option to extend device life in some TE speakers with intractable early leakage. NiD offers several advantages over specialty prostheses, such as those with increased-resistance valves and antifungal properties, typically used to combat early leakage. Patients' report suggests that voicing is easier with the NiD compared with use of the increased-resistance valves available in indwelling and nonindwelling types that are marketed to prevent early leakage. The NiD also provides a less costly alternative to specialty devices, and offers independent management for patients to change the device outside of the clinical setting. To our knowledge, no prior publications have assessed device life of nonindwelling prostheses in subgroups of early leakers. Thus, further prospective studies are required to confirm our results, which suggest that this is a unique indication for the NiD as a nonindwelling alternative to extend device life in patients with early leakage.
Finally, our experience also suggests consideration of the NiD for use in other clinical scenarios. Clinicians may opt for the NiD as a low-cost alternative to the indwelling device at the time of the initial fit when prosthetic durability and patient preferences have not been established. That is, use of the NiD as the initial prosthesis may provide equal durability and outcomes in an uncomplicated patient, with no clear benefit to attempting a costlier indwelling device. If device life and voice are satisfactory, patients may continue to use the NiD as their long-term prosthetic choice, thereby avoiding the unnecessary purchase of more expensive prostheses. We found that almost one-third of patients in this cohort continued to use the NiD as their long-term prosthesis of choice. In addition, the NiD offers the ability to independently change the voice prosthesis, an advantage that avoids the burden of travel, lost work hours, and expenses associated with multiple clinic visits. The current healthcare reimbursement system in the United States poses an additional challenge to TE speakers. The ability to directly purchase the NiD prosthesis may be of significant value to patients whose access to indwelling devices is limited by thirdparty payers. In most instances, patients can directly order the NiD and obtain third-party reimbursement.
CONCLUSION
The NiD voice prosthesis offers satisfactory device life, on a par with that of standard indwelling prostheses in our cohort of TE speakers who tried the NiD. Coupled with published outcomes demonstrating favorable airflow characteristics and superior TE voice, our data suggest that the NiD offers a durable, affordable prosthetic alternative to more expensive indwelling devices in some TE speakers. When reimbursement limits patient access to indwelling devices, the NiD voice prosthesis may provide a comparable experience with the advantage of independent management. A unique indication for NID may be that it improves longevity of device life in patients with a history of early leakage.
